logo-loader
viewAntisense Therapeutics Ltd

Full interview: Antisense Therapeutics further develops therapeutic for Duchenne Muscular Dystrophy with ATL1102

Antisense Therapeutics Limited (ASX:ANP) managing director Mark Diamond updates Proactive on the company’s progress in developing a therapeutic for a severe disease called Duchenne Muscular Dystrophy, or DMD.

The managing director spoke about the importance of the drug ATL1102 that is being progressed through the company’s Phase 2 trial, saying it has shown significant success.

Diamond says some important regulatory interactions necessary for efficient and timely advancement to the next stage of development of ATL1102 are underway.

Quick facts: Antisense Therapeutics Ltd

Price: 0.074 AUD

ASX:ANP
Market: ASX
Market Cap: $36.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Bulls, Bears & Brokers: Alto Capital’s Tony Locantro on Nyrada IPO and small...

Alto Capital investment manager and stock market commentator Tony Locantro updates Proactive on this week's listing of Nyrada Inc (ASX:NYR), a spin-off of Noxopharm Ltd’s (ASX:NOX). He discusses the reasons for the spin-off, including some of the recent and expected trading patterns. Locantro...

1 day, 14 hours ago

2 min read